We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Siemens Healthineers - Laboratory Diagnostics

Download Mobile App

Rapid Detection Technique to Improve Diagnostic Procedure for Bacterial Diseases

By LabMedica International staff writers
Posted on 06 Sep 2023
Print article
Image: Researchers have developed a novel chemosensor-based method for the rapid detection of bacterial toxin (Photo courtesy of Sophia University)
Image: Researchers have developed a novel chemosensor-based method for the rapid detection of bacterial toxin (Photo courtesy of Sophia University)

Lipopolysaccharide (LPS) is a dangerous endotoxin produced by certain bacteria and can trigger harmful immune responses in humans. However, current methods for detecting LPS are slow and complicated. To address this issue, a research team has proposed a system based on a unique fluorescent chemosensor that can detect LPS within minutes, making it ideal for on-site testing in hospitals and pharmaceutical manufacturing facilities.

The COVID-19 pandemic highlighted the need for faster pathogen and toxin screening methods. One such toxin is LPS, which is often referred to as "endotoxins." This molecule is found in the outer membrane of certain bacteria and can be highly harmful, causing fever, inflammation, and even organ failure in severe cases. Surprisingly, despite its prevalence, there are very few effective methods to detect LPS. The current gold standard, the limulus amebocyte lysate (LAL) test, is a manual and time-consuming process that takes several hours and is costly. Other methods for LPS detection are also slow or cumbersome, leading to delays in decision-making in healthcare and pharmaceutical settings. Researchers at Sophia University (Tokyo, Japan) have pioneered a novel approach to rapidly detect LPS in liquid samples. Their new platform has the potential to revolutionize LPS screening.

At the core of this LPS analysis system is a ratiometric fluorescent chemosensor called Zn-dpa-C2OPy. This compound was designed to selectively bind to LPS and exhibits unique fluorescent properties. When not bound to LPS, it forms small spherical vesicles that emit specific-wavelength light upon exposure to UV rays. However, in the presence of LPS, the chemosensor forms complex aggregates with the toxin in the solution. These chemosensor-LPS aggregates emit light at a different wavelength when exposed to UV rays, with their presence further confirmed using spectrometric measurements. To enable high-throughput LPS detection, the researchers combined the chemosensor with a flow injection analysis (FIA) system and a custom dual-wavelength fluorophotometer. This system allows for the easy mixing of a liquid sample with the chemosensor, and the mixture is then analyzed by the fluorophotometer to measure fluorescence changes in response to LPS. By comparing fluorescence intensities, the LPS concentration in the sample can be estimated. One of the major advantages of this system is its speed, as it only takes one minute from sample collection to obtaining results, with the capacity to process 36 samples per hour, making it exceptionally rapid and efficient.

Additionally, the chemosensor-based analysis system is highly sensitive and stable for quantifying LPS, with a detection limit of 11 pM (picomolar), surpassing other reported methods for LPS detection. The system is also simple and animal-friendly, unlike conventional LPS detection methods that use animal resources and may harm them. This makes it an excellent candidate for practical and efficient point-of-care testing for LPS and bacterial contamination in water, clinical, or pharmaceutical samples. With further advancements in this field, the threat of endotoxins can be minimized, enhancing safety in hospitals and improving diagnostic procedures for bacterial diseases.

“Based on this research, an online-endotoxin monitor will be developed and made available for use in real-life situations,” said Takeshi Hashimoto from Sophia University. “Such a monitor could be installed at pharmaceutical production sites, hospital bedsides, and intensive care units to continuously monitor endotoxin concentration in pharmaceutical products, such as water for injection, or the blood of infected patients.”

Related Links:
Sophia University

Platinum Supplier
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Gold Supplier
Blood Glucose Reference Analyzer
Nova Primary
Concentrated Anionic Detergent
Agglutination Plates

Print article


Clinical Chemistry

view channel
Image: The new assays are designed to run on the B•R•A•H•M•S KRYPTOR compact PLUS clinical chemistry analyzer (Photo courtesy of Thermo Fisher)

Breakthrough Immunoassays to Aid in Risk Assessment of Preeclampsia

Preeclampsia is a life-threatening blood pressure condition that can arise during pregnancy and the postpartum phase. This severe pregnancy complication is a primary cause of maternal and fetal mortality... Read more

Molecular Diagnostics

view channel
Image: A CRISPR technology-based diagnostic test detects MPXV in clinical samples with acute precision (Photo courtesy of 123RF)

Powerful Diagnostic Tool Accurately Detects Monkeypox Virus Faster Than Any Method

At present, testing for the monkeypox virus (MPXV) is done mainly in centralized labs, and it can take days to get results due to location and logistical issues. Now, researchers have leveraged cutting-edge... Read more


view channel
Image: The US FDA has cleared HemoScreen point of care CBC for direct capillary sampling (Photo courtesy of PixCell Medical)

Point of Care CBC Analyzer with Direct Capillary Sampling Enhances Ease-of-Use and Testing Throughput

The world’s only 5-part differential Complete Blood Count (CBC) analyzer that is FDA-cleared, CE-marked, and TGA-approved for point-of-care use has now been granted FDA 510(k) clearance for direct capillary... Read more


view channel
Image: Immune cells present long before infection predict flu symptoms (Photo courtesy of Shutterstock.com)

Single Blood Draw to Detect Immune Cells Present Months before Flu Infection Can Predict Symptoms

For decades, if not centuries, scientists have struggled to solve the mystery of why certain individuals fall ill to infections while others remain unaffected. In an impressive development, researchers... Read more


view channel
Image: The Tasso+ device has received CE Mark certification (Photo courtesy of Tasso)

Groundbreaking Blood Lancing Device Obtains Microliter Capillary Whole Blood Samples Painlessly

A convenient, virtually pain-free blood lancet that collects whole liquid blood samples has received CE Mark designation, making the patient-centric, high-volume blood collection solution available in... Read more


view channel
Image: A new electrochemical device can quickly and inexpensively identify people at greatest risk for osteoporosis (Photo courtesy of ACS Central Science, 2023)

Electrochemical Device Identifies People at Higher Risk for Osteoporosis Using Single Blood Drop

With the global increase in life expectancy, the incidence of age-related conditions like osteoporosis is increasing. Osteoporosis, affecting around 200 million individuals worldwide, has a higher incidence... Read more


view channel
Image: The global fully automatic electrolyte analyzers market is projected to reach close to USD 0.77 billion by 2032 (Photo courtesy of 123RF)

Global Fully Automatic Electrolyte Analyzers Market Driven by Surge in Demand for Point-of-Care Testing

Fully automatic electrolyte analyzers can measure the levels of electrolytes in various bodily fluids like blood and plasma. Electrolytes are ions that have an electrical charge and are essential for multiple... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.